Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics’ chief financial officer, Benjamin Hohl, sold 10,000 shares of common stock in an open-market transaction on March 6, 2026, at a weighted-average price of $29.5839 per share. After this sale, he directly owned 51,000 shares. The transaction was executed in multiple trades within a price range of $29.43 to $29.7867.
Enliven Therapeutics, Inc. filing under Form 144 reports proposed resale transactions involving common stock. The filing lists 45,000 shares to be sold through Jefferies LLC with an aggregate amount of $1,324,800.00 and a figure 59,000,000 on 03/09/2026. The filing also itemizes recent sales by Helen Collins: 5,000 shares for $130,878.30 and 40,000 shares for $1,046,985.20 on 02/17/2026.
Enliven Therapeutics (ELVN) is a clinical-stage biotech focused on highly selective small-molecule drugs, led by its BCR-ABL inhibitor ELVN-001 for chronic myeloid leukemia (CML). As of June 30, 2025, non‑affiliate equity was valued at $836.0 million, with 59,800,406 shares outstanding as of February 19, 2026.
Phase 1 ENABLE data in heavily pretreated CML showed a cumulative 47% major molecular response by 24 weeks, with additional Phase 1b cohorts reaching MMR rates up to 53% and deep molecular response up to 35%, alongside a favorable safety profile. ELVN‑001 has Orphan Drug Designation for CML, and a 2L+ Phase 3 pivotal trial (ENABLE‑2) is planned for the second half of 2026.
The company has de-prioritized HER2 inhibitor ELVN‑002 to focus resources on ELVN‑001 and is advancing early research programs, including in Graves’ disease. Enliven holds multiple patent families on its BCR‑ABL technology with potential expirations between 2041 and 2045 and relies on third‑party manufacturers for clinical supply.
Enliven Therapeutics reported fourth quarter and full year 2025 results and highlighted strong progress for its lead CML candidate ELVN-001. Positive initial Phase 1b data in heavily pretreated chronic myeloid leukemia patients showed meaningful major molecular response rates at 80 mg and 60/120 mg once-daily dosing.
The company plans key 2026 milestones, including mid‑year presentation of additional Phase 1 data, regulatory alignment with the FDA on Phase 3 design, and initiation of the pivotal ENABLE-2 trial in the second half of 2026. Recent leadership changes include appointing Rick Fair as CEO and adding Scott Garland to the board.
Enliven ended 2025 with $462.6 million in cash, cash equivalents and marketable securities, expected to fund operations into the first half of 2029. For 2025, R&D expenses were $85.9 million and G&A expenses were $33.8 million, leading to a net loss of $103.7 million, or $1.83 per share.
Enliven Therapeutics director Richard A. Heyman reported an open-market sale of 1,230 shares of common stock at a weighted average price of $26.1759 per share. The sale was made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024 for an associated trust account.
After this transaction, the filing shows 22,647 shares remaining in the indirectly held account that sold the shares, additional indirect holdings of 25,545 shares, and 123,673 shares held directly. Certain indirect holdings are through the Heyman Daigle Trust and RAHD Capital LLC, entities for which he serves as trustee or managing member.
Enliven Therapeutics, Inc.’s Chief Medical Officer Helen Louise Collins exercised stock options and sold shares in a planned transaction. She exercised options for 45,000 shares at $2.48 per share, converting them into 45,000 shares of common stock.
She then sold 45,000 common shares at a weighted average price of $26.1747, with trade prices ranging from $25.76 to $26.695, under a Rule 10b5-1 trading plan adopted on October 19, 2025. After these transactions, she directly held 25,000 shares of common stock and 221,268 option shares, all of which were fully vested and exercisable as of the transaction date.
Enliven Therapeutics Inc. reported proposed resale transactions of common stock via Jefferies LLC for 75,000 shares with an aggregate value of $1,959,750 as of 02/18/2026. The filing also lists multiple executed sales by Joseph Lyssikatos between 12/19/2025 and 02/06/2026, totaling reported proceeds of $4,234,611.77 across five transactions.
Kunkel Lori Anne reported acquisition or exercise transactions in this Form 4 filing.
Enliven Therapeutics director Lori Anne Kunkel received a new stock option grant covering 17,126 shares of the company’s stock. The option was awarded as a derivative security and is held directly. According to the terms, all shares vest in a single installment.
The option will fully vest on the earlier of the first anniversary of Enliven’s 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, provided Kunkel continues serving as a non-employee director through that vesting date.
Enliven Therapeutics director Richard A. Heyman received a grant of stock options for 19,234 shares of Enliven common stock. The options have an exercise price of $0.00 per share. They vest 100% on the earlier of the first anniversary of the 2026 annual stockholder meeting or the 2027 annual stockholder meeting, as long as he continues serving as a non-employee director.